Investment Thesis
Allarity is a pre-commercial biotech company with minimal revenue ($25K) and substantial operating losses (-$2.8M net income) consuming cash at -$4.5M annually. While the company maintains adequate cash reserves ($19.8M) providing 4-5 years of operational runway and moderate leverage, the fundamental business model shows zero product commercialization and 100% dependency on successful drug development. Without demonstrated clinical progress or near-term revenue inflection, equity holders face severe dilution risk from future financing needs.
Strengths
- Adequate cash position of $19.8M providing material operational runway at current burn rate
- Moderate leverage with Debt/Equity ratio of 0.39x, reducing fixed obligations
- Positive current ratio of 1.23x indicates sufficient liquidity for near-term obligations
Risks
- Near-zero revenue ($25K) with no visibility into commercialization timeline or product market fit
- Negative operating cash flow of -$4.5M annually with no path to breakeven demonstrated
- Severe execution risk typical of pre-commercial biotech; cash reserves deplete in 4-5 years without revenue growth or external financing
- Massive negative margins (-11000% net margin) indicating fundamental business model immaturity
Key Metrics to Watch
- Quarterly cash burn rate trend and remaining runway timeline
- Clinical trial progression, regulatory milestones, and near-term approval catalysts
- Top-line revenue growth from any commercialized products
- Cash position and indicators of financing needs or capital raise announcements
Financial Metrics
Revenue
25.0K
Net Income
-2.8M
EPS (Diluted)
$-0.73
Free Cash Flow
-4.6M
Total Assets
34.9M
Cash
19.8M
Profitability Ratios
Gross Margin
-9,060.0%
Operating Margin
-10,752.0%
Net Margin
-11,000.0%
ROE
-39.7%
ROA
-7.9%
FCF Margin
-18,228.0%
Balance Sheet & Liquidity
Current Ratio
1.23x
Quick Ratio
1.23x
Debt/Equity
0.39x
Debt/Assets
80.2%
Interest Coverage
-26.35x
Long-term Debt
2.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:21:17.454261 |
Data as of: 2026-03-31 |
Powered by Claude AI